Stay updated on Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page
- Check5 days agoChange DetectedAdded Thymus cancer to the related conditions and included a Genetic and Rare Diseases Information Center resources link.SummaryDifference0.2%

- Check12 days agoChange DetectedRevision tag updated to v3.4.3, replacing the previous v3.4.2.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check41 days agoChange DetectedRevision: v3.4.2 was added; the notice about lapse in government funding and the Revision: v3.4.1 entry were removed.SummaryDifference0.4%

- Check48 days agoChange DetectedA site-wide notice about a lapse in government funding and potential data delays was added. The site revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check55 days agoChange DetectedAdded a glossary display, introduced a new 'Last Update Submitted that Met QC Criteria' label, and updated the capitalization to 'No FEAR Act Data'. Updated the revision reference from v3.3.4 to v3.4.0.SummaryDifference0.2%

- Check69 days agoChange DetectedRevision: v3.3.4 update shows no substantive changes to the study details, eligibility criteria, locations, or contacts. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page.